Arbutus Biopharma Reports Strong Q1 Net Income of $169.7M Driven by Moderna Settlement Revenue

summarizeSummary

Arbutus Biopharma announced robust first-quarter financial results, reporting a net income of $169.7 million, largely due to the $178.7 million license revenue from the Moderna patent settlement.

check_boxKey Events

• Strong Q1 Financial Performance

  The company reported a net income of $169.7 million ($0.88 per basic share) for Q1 2026, a significant improvement from a $24.5 million net loss in Q1 2025.

• Substantial Revenue from Moderna Settlement

  Total revenue for Q1 2026 was $179.1 million, primarily due to $178.7 million in license revenue from Genevant, representing Arbutus's portion of the upfront Moderna patent settlement payment expected in July 2026.

• Strengthened Cash Position

  Cash, cash equivalents, and marketable securities stood at $95.2 million as of March 31, 2026, with an additional $178.7 million license receivable from Genevant, significantly boosting the company's financial liquidity.

• Imdusiran Receives Fast Track Designation

  The U.S. FDA granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B, a positive development previously announced on April 15, 2026.

auto_awesomeAnalysis

Arbutus Biopharma reported a significant net income of $169.7 million for Q1 2026, a substantial turnaround from a loss in the prior year, primarily driven by $178.7 million in license revenue from the Moderna patent settlement. This confirms the material financial benefits of the settlement, significantly strengthening the company's balance sheet and providing a strong cash runway.